Johnson & Johnson’s Covid-19 vaccine protected macaques in a single shot

All of us are expecting a vaccine within this year to put an end to the ongoing pandemic. Several candidate vaccines, like the mRNA vaccine, are holding on to check the safety and efficacy. Since this kind of work relies on new technology, some scientists still prefer an older type of vaccine that has already proven safe in HIV and Ebola.

A group of scientists, led by Beth Israel Deaconess Medical Center in Boston, discovered a new vaccine, developed from a common cold virus called adenovirus serotype 26 (Ad26). This vector virus carries the spike protein of SARS-CoV-2 into human cells to provoke the immune response. Dan H. Barouch, an immunologist, has worked for this vaccine since January after China exposed the viral genome. They have created a series of vaccine candidates designed to express different variants of the virus spike protein.

- Advertisement -

Read Also: WHO says the current pandemic is one big wave and not seasonal

The vaccine trial

Researchers tested one of seven different single-dose vaccine candidates from the J&J Janssen unit in 32 rhesus monkeys. Then the remaining 20 animals received placebo shots. The team found that the vaccinated macaques develop neutralizing antibodies that protect them from COVID-19. Six weeks after vaccination, the animals exposed to SARS-CoV-2. The animals that received placebo shots showed a high level of damage in their lungs. And the six that got the optimal vaccine did not suffer from the virus, and only one animal showed the lower levels of virus in nasal swabs. The results of the study reported in the journal Nature.

Of the seven variations, Ad26.COV2.S provides the most effective immune response, which will help humans to protect against COVID-19. The mRNA vaccine developed from Moderna and Pfizer needs two doses of vaccine to get the expected results, but in the J&J preclinical study, the single-shot vaccine is enough to impart immunity. This is practically logistic in the global need for the vaccine. Scientists are planning to do human trials with this vaccine shortly to deliver the safety and efficacy of it. This will be investigated by Kathryn E. Stephenson and funded by Janssen Vaccines and Prevention. The vaccine is currently tested in a phase 1/2a study in 1,000 volunteers in the U.S and Belgium, and they are expecting to start the phase 3 trial in September.

Do you want to publish on Apple News, Google News, and more? Join our writing community, improve your writing skills, and be read by hundreds of thousands around the world!

- Advertisement -

Source: MedicalXpress

More from Health – News Landed

+ More than half of the recovered COVID-19 patients develop cardiac problems within a few months, Study reveals
+ Medieval manuscript reveals natural remedy for bacterial infections and fight superbugs

Popular Stories – News Landed

+ How did the ancient Egyptians celebrate their holidays?
+ Sergio Perez ruled out of the British Grand Prix after testing positive for COVID-19

Related Stories

The Hangover IV: Ready for COVID-19 Vaccine? Testing volunteers say not so fast

Pfizer announced on Monday that they had a COVID-19 vaccine with a 90 percent success rate. Unfortunately for some...

Novel nasal sprays assists in preventing SARS-CoV2 transmission

Scientists from Columbia University Vagelos College of Physicians and Surgeons develop a nasal antiviral, which could hamper the transmission...

Featured Stories

Joseph R. Biden and Kamala D. Harris elected to the White House

At around 11:25 a.m. on November 7, 2020, after nearly 90 hours since polls first closed throughout the United...

Match 55 Nov 2: DC win comfortably against RCB, but both the teams qualify

Penultimate league game, and we still have no clue as to which three teams will join Mumbai Indians in...

IPL 2020: Simple break-down of playoffs scenarios for each team

Just 4 matches into the knock-out stage, we see that 6 teams are fighting for the left-over 3 play-offs...

Possibility of habitable planets around red dwarfs

How habitable are planets that orbit the most common type of stars in the Galaxy?  A new study led by...

The Method Behind King Trump’s Madness

Like Shakespeare’s mad King Lear, President Trump realized early on, “In jest, there is truth.” While his quips omit...

Lockdown Lifted: After over 3 months of lockdown, Melbourne, Australia opens up

MELBOURNE, Australia—In a rare bit of good news during this pandemic, one city has finally seen success in their...

Comment Below

The Hangover IV: Ready for COVID-19 Vaccine? Testing volunteers say not so fast

Pfizer announced on Monday that they had a COVID-19 vaccine with a 90 percent success rate. Unfortunately for some...

Novel nasal sprays assists in preventing SARS-CoV2 transmission

Scientists from Columbia University Vagelos College of Physicians and Surgeons develop a nasal antiviral, which could hamper the transmission...